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Bacteroides fragilis, a gram-negative rod,
constitutes 1% to 2% of the normal colonic
bacterial microflora in humans (1,2). It is
frequently associated with extraintestinal infec-
tions such as abscesses and soft tissue infections,
as well as diarrheal diseases in animals and
humans (3-6). Enterotoxigenic B. fragilis (ETBF)
is an emerging enteric pathogen associated with
diarrheal diseases in children, adults, and
animals (4,7-9). The pathogen is unusual in
children during the first year of life, but diarrhea
associated with it is common in children 1 to 5
years of age, which suggests early acquisition of
the organism and maternal protection. The
pathogenicity of B. fragilis is related to its
production of a potent enterotoxin, a zinc-
containing metalloprotease with a molecular
weight of 20,000 (10). The enterotoxin is tight-
junction specific; causes rounding, swelling, and
pyknosis of cultured enterocytes; and induces a
fluid response in ligated intestinal loops and a
cytotoxic response in the HT-29 colon cell line (7).
Ulcerative colitis and Crohn disease are
inflammatory diseases of the gastrointestinal tract
characterized by spontaneous remissions and
relapses. Many microbial pathogens, particularly
Mycobacterium paratuberculosis, paramyxoviruses,
and  Listeria monocytogenes have been implicated
in the etiology of inflammatory bowel disease
(IBD) (11). In addition, enteric pathogens such as
Campylobacter jejuni,  Salmonella,  Shigella,
Yersinia, and Escherichia coli have also been
associated with relapses of IBD (12). We
investigated the prevalence of ETBF in 83
patients with idiopathic IBD, in 18 patients with
routine culture-negative diarrhea, and in a
control population of 69 outpatients (Table 1).
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We identified enterotoxigenic Bacteroides fragilis in stool specimens of patients with
inflammatory bowel disease and other gastrointestinal disorders. The organism was
detected in 11 (13.2%) of 83 patients with inflammatory bowel disease. Of 57 patients
with active disease, 19.3% were toxin positive; none of those with inactive disease had
specimens positive for enterotoxigenic Bacteroides fragilis gene sequences.
Table 1. Demographic characteristics of patients with
inflammatory bowel disease (IBD)
                 Patient group
Diarrhea
Patient   IBD patients Controls
characteristics (n = 83) (n = 18)   (n=69)
Sex
M3 8   4 4 0
F4 5 1 4 2 9
Age (yrs) 10-80 20-75 40-72
Mean = 45.5 45.6 58.2
Duration of
  disease (yrs)
UC   1-13 (5.6)   1-6 (2.6) NA
CD   1-20 (10.5)
Therapeutic
  treatment
5-ASA 58   0   0
5-ASA+Steroids 35   0   0
6-MP/ 20   0   0
 Azathioprine
MTX   1   0   0
Antibiotics   1   1   0
Antidiarrheals   1   3   8Dispatches
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Table 2. Bacteroides fragilis enterotoxin gene amplifica-
tion products in patients with inflammatory bowel disease
(IBD)
Patient group (no.) ETBFa Gene (+)  p valueb
IBD (83) 11 (13.25%) 0.023
Active (57) 11 (19.3%) 0.0026
Inactive  (26)   0
Crohn disease (60)     5
Active  (37)   5
Inactive  (23)   0
Ulcerative colitis (23)     6
Active  (20)   6
Inactive  (3)   0
Diarrhea  (18)   5 (27.8%) 0.0005
Control  (69)   2 (2.89%)
aETBF = enterotoxigenic Bacteroides fragilis
bp value in relation to control group
1A 100-mg sample of stool was suspended in 400 ￿l of TES buffer (50 mM Tris [pH 8], 5 mM EDTA, 50 mM NaCl) and centrifuged at 1,000 x g for 3
min to remove large particles. The supernatant was then centrifuged at 5,000 x g for 7 min. The pellet was washed once in 200 ￿l of TES, and centrifuged
at 5,000 x g for 3 min, and the supernatant was discarded. The pellet was suspended in 100 ￿l of sterile H2O and boiled for 10 min, then centrifuged
at 1,000 x g for 2 min and the supernatant containing the DNA extracted twice with phenol: chloroform: isoamyl alcohol (25:24:1) and precipitated with
ethanol. The sequences of the primers and probes used and PCR conditions were as described (14). Amplification with the outer primers RS-3 (5'
TGAAGTTAGTGCCCAGATGCAGG 3') and RS-4 (5' GCTCAGCGCCCAGTATA TGACC 3') yielded a 367-bp product. Amplification of this product
with the inner primers RS-1 (5' TGCGGCGAACTCGGTTAATGC 3') and RS-2 (5'AGCTGGGTTGTAGACATCCCACTGG' 3') amplified a 290-bp
product. The reaction mixtures were prepared in 1X PCR buffer (50 mM KCl, 20 mM Tris HCl, 2.5 mM MgCl2, 100 ￿g bovine serum albumin per ml
[pH 8.4]) and contained per reaction 20 pmol of the respective primers, 0.1 mM concentrations each of 2'-deoxynucleoside 5'-triphosphate, 2 U of
recombinant DNA polymerase (rTaq) (Perkin Elmer, Norwalk, CT), and 10 ￿l purified fecal DNA. The final reaction volume was adjusted to 100 ￿l with
sterile deonized water. The PCR profile included a denaturing step at 95°C for 30 sec, followed by a 60°C annealing step for 30 sec, with extension at
72°C for 30 sec. The outer PCR was performed for 35 cycles in a thermal cycler (MJ Research). Amplification with the inner primers was done for 30
cycles. Negative controls included a blank containing all PCR reagents with no DNA. As control for amplifiable DNA in the stool specimens, primers
targeting the 16S rRNA gene of enteric bacteria were used as described by Kato et al. (15).
the University of California, Davis. All samples
were collected after informed consent was
obtained. Of the 83 patients in the IBD group, 60
had Crohn disease, and 23 had ulcerative colitis
(Table 2). Active disease was present in 68.6% of
these  patients on endoscopy (20 ulcerative colitis
and 37 Crohn disease patients) in the form of
mucosal erythema and ulceration. In the
miscellaneous diarrhea group, 10 patients had
irritable bowel syndrome; however, no mucosal
erythema, edema, or ulceration was observed. None
of the control patients had a history of diarrhea, and
no erythema or ulceration was observed.
Fecal specimens from the IBD group were
collected endoscopically from patients undergo-
ing colonoscopy or flexible sigmoidoscopy for
evaluation of symptoms of diarrhea or abdominal
pain. The fecal specimens from the 18 diarrhea
patients with negative routine stool cultures and
the 69 controls were collected by endoscopy.
Fecal specimens were cultured for B. fragilis
in the selective medium Bacteroides Bile Esculin
agar. Positive cultures were identified by using
the RapID ANA II Panel (REMEL, Inc, Lenexa,
KS). Plates were incubated anaerobically at 37°C
for 48 hours. The presence of B. fragilis
enterotoxin in the isolates was detected in the
HT-29 colon cell line (13,14). HT-29 cells were
grown and maintained in RPMI medium with
glutamine (Gibco, Life Technologies, Inc., Grand
Island, NY) supplemented with penicillin
(100 IU/ml), streptomycin (100 ￿g/ml) (Sigma,
Saint Louis, MO), and heat-inactivated fetal
bovine serum (Hyclone Laboratories, Inc., Logan,
UT) at 12% in 25-ml flasks at 37°C in 5% CO2. For
the cytotoxicity assay, HT-29 cells were
suspended in 20 ml of medium for each plate, and
180 ￿l/well were placed into 96-well tissue culture
plates (Corning Glass Works, Corning, NY). The
cells were allowed to attach and grow for 2 to 3
days. Supernatants from B. fragilis isolates
grown on Brain Heart Infusion Broth were
filtered through a 0.45-￿m Acrodisk syringe filter
(Gelman Sciences, Ann Arbor, MI), and 20-￿l
serial dilutions were placed into the wells in
duplicate. The plates were incubated at 37°C for 3
to 4 hours under 5% CO2 and examined for typical
cytopathic changes. Cultures were considered
positive for B. fragilis enterotoxin if a visible
cytopathic effect was neutralized by specific
antiserum. The highest dilution of the culture
supernatant producing cytopathic changes in at
least 50% of the cells after 3 to 4 hours of
incubation was considered the cytotoxic titer. For
the neutralization assay, dilutions of 1:25 anti-
enterotoxin rabbit antiserum in phosphate-
buffered saline were mixed with culture
supernatants positive for enteroxin. After
incubation for 30 minutes at 37°C, 20 ￿l of each
mixture was inoculated into HT-29 cells as in the
cytotoxicity assay. Neutralization was indicated
by the lack of cytotoxic effect.
DNA was extracted from the fecal specimens
and amplified by using specific primers (14) to
detect  B. fragilis enterotoxin gene sequences.1 Chi-
square was used to determine statistical significance.Dispatches
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ETBF was cultured from four patients with IBD
and two patients with diarrhea. However,
B. fragilis enterotoxin gene sequences were
detected in the stools of 11 (13.25%) of 83 patients
with idiopathic IBD (five with Crohn disease and
six with ulcerative colitis). All 11 patients
positive for ETBF had active disease by
endoscopic and histologic tests (Table 2). No
ETBF was found in patients with inactive
disease. The Crohn disease patients who were
positive for enterotoxin gene sequences had
superficial mucosal disease. In the control group,
2 (2.9%) of 69 patients were positive for B. fragilis
enterotoxin gene sequences. Enterotoxin amplifi-
cation products were also detected in the
specimens of 5 (27.7%) of 18 patients with
diarrhea due to miscellaneous causes (Table 2).
All the specimens were positive when amplified
with primers specific for the 16S rRNA gene of
enteric bacteria.
Conclusions
The normal colonic microflora of humans is a
complex ecosystem of approximately 500 species
of aerobic and anaerobic microorganisms.
Although the gut of the newborn infant is sterile,
Bacteroides species—the predominant anaerobic
constituent of the colonic flora—appear at
approximately 10 days, are established by 2
weeks, and usually remain constant lifelong (1,2).
In breast-fed infants, Bifidobacterium are the
predominant population, and Bacteroides group
organisms remain undetectable. However, after
weaning, the Bacteroides group organisms
increase and Bifidobacterium organisms de-
crease substantially (16).
The exact etiology of idiopathic IBD is still
unknown, although a potential role for infectious
agents or toxins that may stimulate an
inflammatory response has been suggested
(16,17). For example, Peptostreptococcus,
Coprococcus, and Bacteroides sp. have been
reported in patients with Crohn disease (17). A
role for these microorganisms in the disease
process is also suggested by the clinical responses
of some patients to antibiotics (18). Observations
of  B. thetaiotaomicron in patients with ulcerative
colitis (16) and B. vulgatus in guinea pigs with
experimentally induced ulcerative colitis (19)
suggest that microorganisms may influence the
development or maintenance of intestinal
inflammation in IBD.
In this study, B. fragilis enterotoxin gene
sequences were detected by nested polymerase
chain reaction (PCR) in the stools of 13.2% of
patients with inflammatory bowel disease and
2.9% controls. The low recovery of ETBF in
culture may be due to the length of time from
specimen collection to processing in the
laboratory (most specimens were kept frozen for
at least 2 weeks before culturing). Similar results
have been reported by Sack et al. (9), who found a
marked reduction in the recovery of B. fragilis
with time. Amplification of enterotoxin gene
directly in the stools of these patients appears to
be a more sensitive detection method. In a previous
study (14), we found 100% correlation between
PCR and enterotoxin production in isolates; we
therefore did not routinely perform the HT-29 cell
assay in specimens of these patients.
In the IBD group, all the patients positive for
ETBF had active disease, which suggests an
association with disease activation or flare-up.
ETBF was also found in patients with ulcerative
proctitis, collagenous colitis, and microscopic
colitis. In patients with Crohn disease, ETBF was
usually seen in the colonic superficial inflamma-
tory disease type. The presence of ETBF in IBD
patients may represent alterations of endogenous
bacterial flora, which may be related to either the
etiology or flare-up of the disease or both.
Colonization with ETBF may be acquired early in
life or may be a de novo infection related to flare-
ups of the disease.
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